These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38996147)

  • 21. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
    Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
    Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
    Crestani B; Huggins JT; Kaye M; Costabel U; Glaspole I; Ogura T; Song JW; Stansen W; Quaresma M; Stowasser S; Kreuter M
    Lancet Respir Med; 2019 Jan; 7(1):60-68. PubMed ID: 30224318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
    Inoue Y; Suda T; Kitamura H; Okamoto M; Azuma A; Inase N; Kuwana M; Makino S; Nishioka Y; Ogura T; Takizawa A; Ugai H; Stowasser S; Schlenker-Herceg R; Takeuchi T
    Respir Med; 2021 Oct; 187():106574. PubMed ID: 34564020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
    Valenzuela C; Torrisi SE; Kahn N; Quaresma M; Stowasser S; Kreuter M
    Respir Res; 2020 Jan; 21(1):7. PubMed ID: 31906942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
    Wongkarnjana A; Yanagihara T; Kolb MR
    Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
    Toi Y; Kimura Y; Domeki Y; Kawana S; Aiba T; Ono H; Aso M; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Saito R; Terayama K; Kawashima Y; Nakamura A; Yamanda S; Honda Y; Sugawara S
    Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):74-78. PubMed ID: 32476938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Cottin V
    Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.
    Seibold JR; Maher TM; Highland KB; Assassi S; Azuma A; Hummers LK; Costabel U; von Wangenheim U; Kohlbrenner V; Gahlemann M; Alves M; Distler O;
    Ann Rheum Dis; 2020 Nov; 79(11):1478-1484. PubMed ID: 32759258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial.
    Ogura T; Suda T; Inase N; Nishioka Y; Azuma A; Okamoto M; Takizawa A; Ito T; Rohr KB; Inoue Y
    Respir Investig; 2022 Nov; 60(6):787-797. PubMed ID: 35927208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nintedanib in the treatment of fibrosing interstital lung diseases].
    Lewandowska K
    Pol Merkur Lekarski; 2018 Mar; 44(261):139-141. PubMed ID: 29601564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
    Inoue Y; Kitamura H; Okamoto M; Ogura T; Nishioka Y; Kuwana M; Taniguchi A; Ito T; Rohr KB; Suda T
    Respir Investig; 2024 Jul; 62(4):589-596. PubMed ID: 38692040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis.
    Corte T; Bonella F; Crestani B; Demedts MG; Richeldi L; Coeck C; Pelling K; Quaresma M; Lasky JA
    Respir Res; 2015 Sep; 16():116. PubMed ID: 26400368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities.
    Glaspole I; Bonella F; Bargagli E; Glassberg MK; Caro F; Stansen W; Quaresma M; Orsatti L; Bendstrup E
    Respir Res; 2021 Apr; 22(1):125. PubMed ID: 33902584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis.
    Uchida Y; Ikeda S; Sekine A; Katano T; Tabata E; Oda T; Okuda R; Kitamura H; Baba T; Komatsu S; Ogura T
    Respir Investig; 2021 Jan; 59(1):99-105. PubMed ID: 32891571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.